Slope of Kidney Function and Its Association with Longitudinal Mortality and Cardiovascular Disease among Individuals

Paula F Orlandi1,2, Dawei Xie3,2, Wei Yang3,2

  • 1Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania paulaorlandi66@gmail.com.

Insights

Steep declines in estimated glomerular filtration rate (eGFR) increase risks of death and cardiovascular events in CKD patients. However, improving eGFR did not show increased risks, suggesting eGFR slopes are valuable for clinical assessment.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Geriatrics

Background:

  • Estimated glomerular filtration rate (eGFR) decline is a known risk factor for adverse outcomes.
  • A U-shaped association between eGFR slopes and risks of death and cardiovascular events has been suggested.
  • Poor outcomes in individuals with rising eGFR may be linked to clinical deterioration indicators like sarcopenia.

Purpose of the Study:

  • To investigate the association between eGFR slopes and risks of death or cardiovascular events.
  • To account for multiple confounders in the relationship between eGFR trajectories and clinical outcomes.
  • To assess the prognostic value of eGFR changes in patients with moderate to severe chronic kidney disease (CKD).

Main Methods:

  • Studied 2738 individuals with moderate to severe CKD from the Chronic Renal Insufficiency Cohort (CRIC) Study.
  • Employed linear mixed-effects models to estimate eGFR slopes using up to four annual assessments.
  • Utilized Cox proportional hazards models to analyze the association between eGFR slopes and risks of death and cardiovascular events.

Main Results:

  • eGFR slopes exhibited a bell-shaped distribution, with an average decline of -1.5 ml/min per 1.73 m² per year.
  • Steeper declines in eGFR were progressively associated with increased risks of death (HR, 1.23) and cardiovascular events (HR, 1.19).
  • No increased risks of death or cardiovascular events were observed with eGFR rises or declines less steep than average.

Conclusions:

  • Steep eGFR declines are linked to increased risks of death and cardiovascular events in moderate to severe CKD.
  • eGFR improvement was not associated with increased adverse outcomes.
  • eGFR slopes may serve as a valuable tool for clinical risk assessment in adults with CKD.
Abstract

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
391
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
90
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
242
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
397
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
188
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
299